Glybuzole

Synonyms: Desaglybuzole
Glybuzole(Desaglybuzole)是一种口服有效的降糖药,可促进胰腺β细胞分泌胰岛素并抑制胰腺α细胞分泌胰高血糖素,从而降低血糖水平以及精氨酸刺激的血浆胰高血糖素水平,可用于糖尿病相关研究。
产品编号: MS-C64414 CAS No.: 1492-02-0 分子式: C12H15N3O2S2 分子量: 297.40
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价

产品描述

Glybuzole(Desaglybuzole)是一种口服有效的降糖药,可促进胰腺β细胞分泌胰岛素并抑制胰腺α细胞分泌胰高血糖素,从而降低血糖水平以及精氨酸刺激的血浆胰高血糖素水平,可用于糖尿病相关研究。

生物实验数据

生物活性 Glybuzole (Desaglybuzole) is an orally effective hypoglycemic agent that promotes insulin secretion from pancreatic β cells and inhibits glucagon secretion from pancreatic α cells, thereby reducing blood glucose levels and arginine-stimulated plasma glucagon levels, and can be used in diabetes-related research.
体外研究
(In Vitro)

Glybuzole (4-40 μg/mL; 24 h) 可与人血清白蛋白 (HSA) 结合,结合常数为 15.6 μM。

体内研究
(In Vivo)

Glybuzole (100 mg;动脉内给药;持续 10 分钟) 在麻醉杂种犬中可显著降低血糖、刺激胰腺胰岛素分泌并抑制胰高血糖素分泌。
Glybuzole (50-100 mg/kg;口服;单次给药,连续 29 天) 可降低正常雄性 Wistar 大鼠的血糖水平,单次给予 50 mg/kg 剂量后的血浆半衰期为 7 小时,且主要经粪便和胆汁排泄。
Glybuzole (50 mg/kg;口服;单次给药) 在经苯巴比妥预处理的雄性 Wistar 大鼠中降糖效力下降,且单次给予 50 mg/kg 剂量后其血浆半衰期缩短至 4.5 小时。
Glybuzole (50 mg/kg;口服;单次给药) 在单次给予 50 mg/kg 剂量后,其血浆半衰期延长至 28 小时,并可使经 SKF 525A 预处理的雄性 Wistar 大鼠持续降低血糖。
Glybuzole (50 mg/kg;口服;单次给药) 在单次给予 50 mg/kg 剂量后,其血浆半衰期延长至 34 小时,与正常大鼠相比尿排泄量增加 2.5 倍,并可使经 Carbon tetrachloride (MS-X51453) 预处理的雄性 Wistar 大鼠血糖持续降低。
Glybuzole (20-100 mg/kg;口服、静脉注射;单次给药) 可降低正常雄性家兔的血糖水平。

Animal Model: mongrel (adult, 18-28 kg, anesthetized)
Dosage: 100 mg
Administration: intra-arterial; over 10 minutes
Result: Decreased femoral artery blood glucose to 72.0 mg/100ml at 40 minutes post-infusion.
Increased pancreatic vein plasma insulin to 164.0 μU/mL at 1 minute and 352.3 μU/mL at 3 minutes post-infusion, then declined toward baseline by 40 minutes.
Decreased pancreatic vein plasma glucagon from baseline to a nadir of 0.92 mμg/mL at 6 minutes post-infusion, then returned to baseline.
Animal Model: Wistar (male, body weight 190-210 g)
Dosage: 50 mg/kg (single dose); 100 mg/kg (29 consecutive daily doses followed by a single 100 mg/kg dose)
Administration: p.o.; single dose; 29 consecutive days
Result: Reached peak blood concentration of ≈100 μg/mL at 1 hour, with a plasma half-life of 7 hours after a single 50 mg/kg oral dose.
Excreted 20.6% of administered radioactivity in urine and 74.2% in feces over 96 hours; excreted 91.1% of administered radioactivity in bile within 48 hours after a single 50 mg/kg oral dose.
Accounted for 88.6-94.4% of plasma radioactivity as unchanged drug over 1-24 hours, with metabolites I and II making up 1.5-3.6% and 2.3-8.5% respectively after a single 50 mg/kg oral dose.
Accounted for 97.5-97.8% of plasma radioactivity as unchanged drug over 1-24 hours, with metabolites I and II making up 0.3-1.4% and 1.1-1.9% respectively after 30 days of continuous 100 mg/kg dosing.
Reduced blood glucose levels in normal rats, with the lowest levels observed at 1-3 hours post-administration after a single 50 mg/kg oral dose.
Animal Model: Wistar (male, body weight 190-210 g, pretreated with phenobarbital)
Dosage: 50 mg/kg
Administration: p.o.; single dose
Result: Reached peak blood concentration at 1 hour, with a plasma half-life of 4.5 hours after a single 50 mg/kg oral dose.
Excreted 27.8% of administered radioactivity in urine over 96 hours after a single 50 mg/kg oral dose.
Accounted for 73.0-92.7% of plasma radioactivity as unchanged drug over 1-12 hours, with metabolite II increasing to 22.1% at 12 hours after a single 50 mg/kg oral dose.
Showed reduced blood glucose-lowering activity compared to normal rats after a single 50 mg/kg oral dose.
Animal Model: Wistar (male, body weight 190-210 g, pretreated with SKF 525A)
Dosage: 50 mg/kg
Administration: p.o.; single dose
Result: Reached peak blood concentration at 3 hours, with a plasma half-life of 28 hours after a single 50 mg/kg oral dose.
Excreted 27.8% of administered radioactivity in urine and 71.6% in feces over 96 hours after a single 50 mg/kg oral dose.
Accounted for 93.9-99.9% of plasma radioactivity as unchanged drug over 1-24 hours, with minimal metabolites detected before 24 hours after a single 50 mg/kg oral dose.
Produced a sustained blood glucose-lowering effect in pretreated rats after a single 50 mg/kg oral dose.
Animal Model: Wistar (male, body weight 190-210 g, pretreated with carbon tetrachloride)
Dosage: 50 mg/kg
Administration: p.o.; single dose
Result: Reached peak blood concentration at 3 hours, with a plasma half-life of 34 hours after a single 50 mg/kg oral dose.
Excreted 50% of administered radioactivity in urine and 36% in feces over 96 hours; excreted 66.3% of administered radioactivity in bile within 48 hours after a single 50 mg/kg oral dose.
Produced a sustained blood glucose-lowering effect in pretreated rats after a single 50 mg/kg oral dose.
Animal Model: (male, body weight 2.5 kg)
Dosage: 20-100 mg/kg (20 mg/kg i.v.; 100 mg/kg p.o.)
Administration: p.o.; i.v.; single dose
Result: Reduced blood glucose levels in normal rabbits, with the lowest levels observed at 3 hours post-administration after a single 100 mg/kg oral dose.
Reduced blood glucose levels in normal rabbits, with the lowest levels observed at 2 hours post-administration after a single 20 mg/kg intravenous dose.

化学信息

分子量 297.40
分子式 C12H15N3O2S2
CAS No. 1492-02-0
别名 Desaglybuzole

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础